When a patient is hospitalized, their families expect them to get adequate treatment and healthcare facilities. However, the increasing morbidity rate of nosocomial infections presents a completely different picture altogether. Since hospitals are filled with sick people, the chances of getting an infection can drastically increase if proper hygiene is not maintained. Hospital authorities understand and acknowledge the seriousness of the problem. Hence, to combat the rising incidence of hospital acquired diseases, authorities have taken recourse to appropriate testing and diagnostic procedures that can help with the treatment and prevention of the disease.
High Neonatal and Geriatric Population to Drive Global Hospital Acquired Disease Testing Market
High neonatal population in developing countries and increasing geriatric population worldwide are the major factors impacting for global hospital acquired disease testing market. In addition, patients with weak immune system and those exposed to inadequate healthcare conditions are also highly vulnerable to nosocomial infections. Getting in contact with nosocomial infection prolongs the hospital stay of patients, which unduly increases the cost to the patients. To counter the growing prevalence of hospital acquired diseases, many diagnostic tests are introduced in the market, though approximately 70% of the pathogens spreading such infections have become resistant to at least one type of anti-bacterial drug commonly used in nosocomial infection treatment. This has further intensified the challenge for healthcare professionals.
As a potent solution, the healthcare industry has developed a microorganism-specific detection test, which at present is highly in demand from healthcare professionals worldwide for better assessment of disease. Some of the major techniques used in the market today for nosocomial infection diagnosis are PCR, molecular diagnostics, solid phase hybridization, and microarrays. The development of NAT or nucleic acid testing diagnostic products for accurate diagnosis of hospital acquired diseases has paved the way for several players to enter the market.
Hospital Acquired Disease Testing Market to Grow at 19.3% CAGR
According to a research report by Transparency Market Research, the global hospital acquired disease testing market was valued at US$2.2 billion in 2012 and is projected to be worth US$7.5 billion by 2019. If these estimates by research analysts are justified, the hospital acquired disease testing market is likely to grow at a strong CAGR of 19.3% between 2013 and 2019.
To reduce the high incidence of hospital acquired infections, governments across developed countries such as the U.S., Australia, and Canada, and major economies of Europe have acted to control and prevent the prevalence of nosocomial infections through several inspective and in-house initiatives. Authorities such as the CDC (Centers for Disease Control and Prevention) in the U.S. and National Health and Medical Research Council in Australia have designed rules and recommendation for hospitals and other healthcare institution to manage the numerous types of nosocomial infections.
Asia Pacific to Emerge as a Lucrative Market for HAI Diagnostics
Diagnostic methods such as quantitative PCR, blood culture tests, wound culture, tissue biopsy, and latex agglutination are performed most commonly to diagnose nosocomial infections. HAI diagnostics contributes to 64% of the total molecular diagnostic market. Advent of contemporary diagnostic tools with reduced turnaround time and greater accuracy will further propel the HAI testing market. Asia Pacific is the most lucrative market for HAI testing owing to the high incidence of hospital acquired diseases in countries such as India and China. Geographically, North America dominates the global market for hospital acquired disease testing market at present.